Home / Private raises / Linnaeus Therapeutics, Inc.
Linnaeus Therapeutics, Inc.
Biotechnology · Haddonfield, New Jersey · $3.7M sold across 1 offering
Form D filings (1)
| Filed | Form | Sold | Offered | Investors | Exemption | Securities | First sale | |
|---|---|---|---|---|---|---|---|---|
| 2026-11-18 | D (new) | $3.7M | $10.0M | 4 | 506(b) | Equity | Nov 16 | SEC ↗ |
An update (D/A) restates the running total of its offering, so the total above counts each offering's latest figure once.
Issuer
| Industry | Biotechnology |
| Located | Haddonfield, New Jersey |
| Entity | Corporation |
| Incorporated | Delaware |
| Minimum investment | $1 |
| SEC CIK | 1752026 |
People named in the latest filing
| Name | Role |
|---|---|
| Patrick Mooney | Director |
| Chris Arendt | Director |
| Michael Poisel | Director |
| Todd Thomson | Director |
| James 30 Washington Avenue, Suite F | Director |
| John Lepping | Director |
Names and roles as filed with the SEC. Addresses are not shown.
Source: SEC EDGAR Form D filings. Amounts are self-reported by the issuer. Not investment advice.
How are we doing?
